- Home
- PRPL vs LCTX Comparison
PRPL vs LCTX Comparison
Compare PRPL & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPL
- LCTX
- Stock Information
- Founded
- PRPL 2010
- LCTX 1990
- Country
- PRPL United States
- LCTX United States
- Employees
- PRPL N/A
- LCTX N/A
- Industry
- PRPL Home Furnishings
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRPL Consumer Discretionary
- LCTX Health Care
- Exchange
- PRPL Nasdaq
- LCTX Nasdaq
- Market Cap
- PRPL 96.8M
- LCTX 95.2M
- IPO Year
- PRPL N/A
- LCTX N/A
- Fundamental
- Price
- PRPL $0.79
- LCTX $0.45
- Analyst Decision
- PRPL Hold
- LCTX Strong Buy
- Analyst Count
- PRPL 2
- LCTX 5
- Target Price
- PRPL $1.25
- LCTX $4.20
- AVG Volume (30 Days)
- PRPL 1.0M
- LCTX 930.0K
- Earning Date
- PRPL 05-06-2025
- LCTX 05-13-2025
- Dividend Yield
- PRPL N/A
- LCTX N/A
- EPS Growth
- PRPL N/A
- LCTX N/A
- EPS
- PRPL N/A
- LCTX N/A
- Revenue
- PRPL $472,015,000.00
- LCTX $9,499,000.00
- Revenue This Year
- PRPL N/A
- LCTX N/A
- Revenue Next Year
- PRPL $5.62
- LCTX $232.66
- P/E Ratio
- PRPL N/A
- LCTX N/A
- Revenue Growth
- PRPL N/A
- LCTX 6.19
- 52 Week Low
- PRPL $0.56
- LCTX $0.37
- 52 Week High
- PRPL $1.59
- LCTX $1.40
- Technical
- Relative Strength Index (RSI)
- PRPL 59.52
- LCTX 47.88
- Support Level
- PRPL $0.76
- LCTX $0.37
- Resistance Level
- PRPL $0.97
- LCTX $0.48
- Average True Range (ATR)
- PRPL 0.07
- LCTX 0.04
- MACD
- PRPL 0.03
- LCTX 0.00
- Stochastic Oscillator
- PRPL 53.74
- LCTX 49.73
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.